1. Home
  2. CDNL vs ABUS Comparison

CDNL vs ABUS Comparison

Compare CDNL & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardinal Infrastructure Group Inc. Class A Common Stock

CDNL

Cardinal Infrastructure Group Inc. Class A Common Stock

HOLD

Current Price

$31.16

Market Cap

888.6M

Sector

N/A

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$5.00

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDNL
ABUS
Founded
2013
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
888.6M
1.0B
IPO Year
2025
2008

Fundamental Metrics

Financial Performance
Metric
CDNL
ABUS
Price
$31.16
$5.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$38.00
$5.00
AVG Volume (30 Days)
488.3K
4.9M
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
55.26
EPS
0.53
0.84
Revenue
$456,045,369.00
$14,083,000.00
Revenue This Year
$50.30
N/A
Revenue Next Year
$8.41
$239.71
P/E Ratio
$59.91
$6.04
Revenue Growth
44.69
128.21
52 Week Low
$21.98
$3.50
52 Week High
$96.40
$5.45

Technical Indicators

Market Signals
Indicator
CDNL
ABUS
Relative Strength Index (RSI) 30.55 51.78
Support Level $23.33 $4.99
Resistance Level $35.76 $5.06
Average True Range (ATR) 2.38 0.08
MACD 0.37 -0.03
Stochastic Oscillator 4.86 11.76

Price Performance

Historical Comparison
CDNL
ABUS

About CDNL Cardinal Infrastructure Group Inc. Class A Common Stock

Cardinal Infrastructure Group Inc provides a comprehensive suite of infrastructure services to the residential, commercial, industrial, municipal, and state infrastructure markets. The company provides wet utility installations (water, sewer, and stormwater systems), as well as grading, site clearing, erosion control, drilling and blasting, paving, and other related site services. It derives all revenue in the United States of America from construction projects based in North Carolina and South Carolina.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: